AbbVie
ABBV · New York Stock Exchange · Health Care
Shareholder advocacy aimed at AbbVie
6 recorded campaigns from 4 organizations.
Zevin Asset Management at AbbVie
Disclose more about the company's lobbying, including payments to trade associations and how the board oversees them.
Friends Fiduciary Corporation at AbbVie
Establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.
Trinity Health at AbbVie
Set up and report on a way of weighing what an extended patent monopoly would do to people's ability to get the medicine, before deciding whether to apply for follow-on patents.
As You Sow at AbbVie
Stop giving money to politicians and political committees working to restrict access to reproductive health care, or explain how that giving squares with what the company says it stands for.
United Church Funds at AbbVie
Report annually on how much risk from public concern over drug-pricing strategy is factored into executive incentive-compensation arrangements.
United Church Funds, on behalf of Interfaith Center on Corporate Responsibility members at AbbVie
The resolution asked AbbVie's compensation committee to report each year on whether executives were being rewarded, through incentive pay, for pricing strategies that drew public criticism over drug costs.
What shareholders voted on
From AbbVie’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows | Shareholder proposal | Mercy Investment Services | 39.6% | Failed |
| The compensation of AbbVie’s named executive officers, as follows | Say on pay | 94.7% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows | Auditor | 98.5% | Passed | |
| Election of Melody B. Meyer | Director | 98.3% | Passed | |
| Election of Frederick H. Waddell | Director | 93.7% | Passed | |
| Election of Robert A. Michael | Director | 93.4% | Passed | |
| Election of Jennifer L. Davis | Director | 93.1% | Passed |
2025
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to implement simple majority voting, as follows | Shareholder proposal | 49.3% | Failed | |
| The compensation of AbbVie’s named executive officers, as follows | Say on pay | 93.9% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2025, as follows | Auditor | 98.2% | Passed | |
| Election of Brett J. Hart | Director | 97.2% | Passed | |
| Election of William H.L. Burnside | Director | 95% | Passed | |
| Election of Edward J. Rapp | Director | 94.6% | Passed | |
| Election of Thomas C. Freyman | Director | 94.1% | Passed |
2023
2022
2021
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows | Shareholder proposal | 36.1% | Failed | |
| The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows | Shareholder proposal | 28.4% | Failed | |
| The compensation of AbbVie’s named executive officers listed in the proxy statement for the 2021 annual meeting, as follows | Say on pay | 89.9% | Passed | |
| The Amended and Restated 2013 Employee Stock Purchase Plan for Non-U.S. Employees, as follows | Company proposal | 97.3% | Passed | |
| The Amended and Restated 2013 Incentive Stock Program, as follows | Company proposal | 95% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2021, as follows | Auditor | 97.4% | Passed | |
| Election of Rebecca B. Roberts | Director | 96.9% | Passed | |
| Election of Roxanne S. Austin | Director | 96.7% | Passed | |
| Election of Richard A. Gonzalez | Director | 94% | Passed | |
| Election of Glenn F. Tilton | Director | 89.7% | Passed |
2020
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows | Shareholder proposal | 29.7% | Failed | |
| The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows | Shareholder proposal | 27.7% | Failed | |
| The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows | Shareholder proposal | 24.4% | Failed | |
| The compensation of AbbVie’s named executive officers listed in the proxy statement for the 2020 annual meeting, as follows | Say on pay | 94.4% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2020, as follows | Auditor | 99.4% | Passed | |
| Election of Melody B. Meyer | Director | 99.4% | Passed | |
| Election of Frederick H. Waddell | Director | 99.2% | Passed | |
| Election of Edward M. Liddy | Director | 98.2% | Passed | |
| Election of Robert J. Alpern | Director | 97.9% | Passed |
2019
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows | Shareholder proposal | 39% | Failed | |
| The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows | Shareholder proposal | 25% | Failed | |
| The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows | Shareholder proposal | United Church Funds | 21.9% | Failed |
| The compensation of AbbVie’s named executive officers listed in the proxy statement for the 2019 annual meeting, as follows | Say on pay | 91.9% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2019, as follows | Auditor | 99.4% | Passed | |
| Election of Edward J. Rapp | Director | 99.4% | Passed | |
| Election of Brett J. Hart | Director | 98.4% | Passed | |
| Election of William H.L. Burnside | Director | 98.3% | Passed |
2018
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| The stockholders did not approve a stockholder proposal to separate chair and CEO, as follows | Shareholder proposal | 38.6% | Failed | |
| The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows | Shareholder proposal | 24.3% | Failed | |
| The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows | Shareholder proposal | 21.8% | Failed | |
| The compensation of AbbVie’s named executive officers listed in the proxy statement for the 2018 annual meeting, as follows | Say on pay | 95.4% | Passed | |
| The appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2018, as follows | Auditor | 99.3% | Passed | |
| Election of Rebecca B. Roberts | Director | 99.1% | Passed | |
| Election of Roxanne S. Austin | Director | 98.9% | Passed | |
| Election of Glenn F. Tilton | Director | 98.2% | Passed | |
| Election of Richard A. Gonzalez | Director | 97% | Passed |
Proxy statements and vote results
Straight from AbbVie’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-05-12 |
| 2026 | Proxy statement | 2026-03-23 |
| 2025 | Vote results | 2025-05-13 |
| 2025 | Proxy statement | 2025-03-24 |
| 2024 | Proxy statement | 2024-03-18 |
| 2023 | Vote results | 2023-05-10 |
| 2023 | Proxy statement | 2023-03-20 |
| 2022 | Vote results | 2022-05-11 |
| 2022 | Proxy statement | 2022-03-21 |
| 2021 | Vote results | 2021-05-10 |
| 2021 | Proxy statement | 2021-03-22 |
| 2020 | Vote results | 2020-05-12 |
| 2020 | Proxy statement | 2020-03-23 |
| 2019 | Vote results | 2019-05-06 |
| 2019 | Proxy statement | 2019-03-22 |
| 2018 | Vote results | 2018-05-08 |
| 2018 | Proxy statement | 2018-03-19 |
Do you represent AbbVie? Claim this profile to respond to the campaigns listed here.